cancer therapeutics Market Research Reports

"...... ts in the upper part of throat, behind the nose. This area is called the nasopharynx. The risk factors of nasopharyngeal cancer may include Epstein-Barr virus. Symptoms of nasopharyngeal cancer may include blurry or double vision, difficulty speaking......"

"...... s typically of uterine, gastrointestinal or soft tissue origin. Symptoms include a noticeable lump or swelling, pain, if it presses on nerves or muscles and a blockage in the stomach or intestines or gastrointestinal bleeding if the tumor is located ......"

"...... ude local pain, local swelling, local warmth, dilated blood vessels pain and swelling of the bone, pathological fractures, neurological and vascular changes. Report Highlights Global Markets Direct's Ph......"

"...... type of slow growing leukemia that affects developing B-lymphocytes (also known as B-cells). Symptoms include swollen lymph nodes (glands) in the neck, under the arms or in the groin, pain or discomfort under the ribs on the left side, due to an enla......"

"...... type and consisting of epithelial and/or spindle cell components. Symptoms include swelling, mass that may or may not be accompanied by pain and limping or difficulty using legs, arms, hands or feet. Treatment includes surgery, radiation therapy and......"

"...... > Commercialization of TIL therapy Adoptive immunotherapy with genetically engineered T cells bearing chimeric antigen receptors (CARs) Manufacturing issues with CAR T-cell therapies General conclusions on the progr......"

"...... Third generation Antiandrogens- What left for AR-V7 mutants after TOK-001 failure? Late Stage Prostate Cancer Pipeline drugs – AKT inhibitors or PARP inhibitors or a new MoA combination with Antiandrogen or IO combo - Competing to Xtand......"

"...... ries are driving growth in the caner immunotherapy market. However, stringent regulatory policies and side-effects associated with cancer therapy are the major factors restraining the growth of this market. The global cancer immunotherapy mar......"

"...... ome instances, produced impressive gains in patient response. Today they are one of the most fundamental strategies for treating patients with hematological malignancies and solid tumors. This report explores the next level of therapy, combining anti......"

"...... any disease, prostate cancer ranks eleventh; and it ranks sixth in terms of cancer–related mortality in men. The prostate cancer market has a huge demand for new and novel drugs that address unmet needs such as improved survival time, less toxi......"